Stocktoria
Neuronetics, Inc. STIM
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus · website · IPO 2018-06-28
Neuronetics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 48.5% | 72.3% | 72.5% | 76.3% | 78.9% |
| Operating margin | -21.1% | -46.2% | -42.8% | -53.8% | -49.8% |
| Net margin | -26.1% | -58.4% | -42.3% | -57.0% | -56.4% |
| Return on assets | -27.6% | -31.0% | -26.1% | -31.8% | -22.1% |
| Return on equity | -148.6% | -137.5% | -88.3% | -65.1% | -36.6% |
| Debt / equity | 2.51× | 1.73× | 1.73× | 0.63× | 0.41× |
| Current ratio | 2.02 | 1.86 | 4.73 | 2.98 | 7.34 |
| Revenue growth | 99.2% | 5.0% | 9.4% | 17.9% | 12.3% |
Source: SEC EDGAR filings · CIK 0001227636 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.